

List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6035052/yusuf-yazici-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59 papers	854 citations	13 h-index	28 g-index
66 ext. papers	1,103 ext. citations	7.8 avg, IF	4.62 L-index

#	Paper	IF	Citations
59	Behçet syndrome: a contemporary view. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 107-119	8.1	167
58	Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1510-8	59.2	157
57	Behçet's syndrome. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 429-35	4.9	103
56	Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2008</b> , 66, 77-85		66
55	Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1918-1928	59.2	65
54	Ocular Involvement of Behçet's Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 49, 298-306	12.3	36
53	Criteria for Behçet's disease with reflections on all disease criteria. <i>Journal of Autoimmunity</i> , <b>2014</b> , 48-49, 104-7	15.5	34
52	Treatment of rheumatoid arthritis: we are getting there. <i>Lancet, The</i> , <b>2009</b> , 374, 178-80	40	27
51	Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 888-89	2.2	19
50	Some concerns about adverse event reporting in randomized clinical trials. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2008</b> , 66, 143-5		16
49	Promising new treatments for rheumatoid arthritis - the kinase inhibitors. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2011</b> , 69, 233-7		16
48	Treat-to-target: measures. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, S7-9	2.2	15
47	Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet syndrome for patients in the US and Japan: data from a large, three-center cohort study. <i>Modern Rheumatology</i> , <b>2013</b> , 23, 547-553	3.3	13
46	MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sites. <i>RMD Open</i> , <b>2017</b> , 3, e000391	5.9	13
45	Biomarkers in vasculitis. <i>Current Opinion in Rheumatology</i> , <b>2018</b> , 30, 30-35	5.3	12
44	A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 215	5.7	7
43	The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	7

42	Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , <b>2018</b> , 5, 216-223	1.7	6
41	Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. <i>Rheumatology</i> , <b>2020</b> , 59, 2090-2098	3.9	6
40	Behçet syndrome. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 67	51.1	6
39	MBDA: what is it good for?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, e72	2.4	5
38	Management of Behçet syndrome. <i>Current Opinion in Rheumatology</i> , <b>2020</b> , 32, 35-40	5.3	5
37	Diagnosis and/or classification of vasculitis: different?. <i>Current Opinion in Rheumatology</i> , <b>2016</b> , 28, 3-7	5.3	4
36	The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 477-483	2.2	4
35	Informed consent: time for more transparency. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, 121	5.7	3
34	Comment on: 'It can't be zero!' Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , <b>2021</b> , 60, e28-e29	3.9	3
33	Vasculitis update, 2007. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2007</b> , 65, 212-4		3
32	Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2007</b> , 65, 300-5		3
31	Systemic vasculitis treatment and monitoring update, 2008. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2008</b> , 66, 228-30		3
30	Safety reporting in randomized clinical trials - a need for improvement. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2009</b> , 67, 209-10		3
29	Pulmonary artery aneurysms in Behçet's syndrome: a review of the literature with emphasis on geographical differences. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S54-9	2.2	3
28	Apremilast for the treatment of Behçet's syndrome. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 677-681	1.1	2
27	There was less self-critique among basic than in clinical science articles in three rheumatology journals. <i>Journal of Clinical Epidemiology</i> , <b>2014</b> , 67, 654-7	5.7	2
26	Treatment options for rheumatoid arthritis beyond TNF- $\alpha$ inhibitors. <i>Expert Review of Clinical Pharmacology</i> , <b>2010</b> , 3, 663-6	3.8	2
25	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1315-6	9.5	2

24	THU0303 THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHËT'S SYNDROME <b>2019</b> ,		2
23	Monitoring response to treatment in rheumatoid arthritis--which tool is best suited for routine "real world" care?. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2007</b> , 65 Suppl 1, S25-8		2
22	Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 120, 7-17	2.2	2
21	Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 894-901	2.6	1
20	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 724	4.7	1
19	173 Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase III clinical trial data. <i>Rheumatology</i> , <b>2018</b> , 57,	3.9	1
18	Monitoring outcomes of arthritis and longitudinal data collection using patient questionnaires in routine care. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2006</b> , 64, 40-4		1
17	Informed consent--practical considerations. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2010</b> , 68, 127-9		1
16	Apremilast for oral ulcers associated with active BehËt's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 80-87	2.2	1
15	Wnt Signaling in Osteoarthritis: a 2017 Update. <i>Current Treatment Options in Rheumatology</i> , <b>2017</b> , 3, 101-111	1.3	0
14	Kinase inhibitors for the treatment of rheumatoid arthritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2012</b> , 70, 204-7		0
13	Initial visit symptoms in probable BehËt's syndrome is predictive of ISG criteria fulfillment in BehËt's syndrome: data from New York and Amsterdam cohorts. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 43-46	2.2	0
12	Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, e54	2.4	
11	Letter from the Editor. <i>Biologics in Therapy</i> , <b>2011</b> , 1, 2		
10	Severe adverse reactions are rare with infusions of infliximab in a community setting. <i>Evidence-based Nursing</i> , <b>2010</b> , 13, 107-8	0.3	
9	The relationship between body composition, disease activity, and functional status in adults with rheumatoid arthritis (1031.15). <i>FASEB Journal</i> , <b>2014</b> , 28, 1031.15	0.9	
8	BehËt's Syndrome289-298		
7	Functional Status Measures and Indices in Rheumatoid Arthritis: Comment on the Articles by Barber et al and England et al. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1185-1186	4.7	

6	Correspondence on 'classification criteria: time for a rethink' by D Porter. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4
5	Databases in routine care: possible and necessary. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2007</b> , 65, 127-31	
4	Corticosteroids as disease modifying drugs in rheumatoid arthritis treatment. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , <b>2012</b> , 70 Suppl 1, 11-3	
3	Effect size, the misnomer. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> ,	2.2
2	Initial visit symptoms in probable Behçet's syndrome is predictive of ISG criteria fulfillment in Behçet's syndrome: data from New York and Amsterdam cohorts. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 43-46	2.2
1	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 80-87	2.2